417 related articles for article (PubMed ID: 27835975)
1. Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome.
Kusaka H; Koibuchi N; Hasegawa Y; Ogawa H; Kim-Mitsuyama S
Cardiovasc Diabetol; 2016 Nov; 15(1):157. PubMed ID: 27835975
[TBL] [Abstract][Full Text] [Related]
2. SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob
Adingupu DD; Göpel SO; Grönros J; Behrendt M; Sotak M; Miliotis T; Dahlqvist U; Gan LM; Jönsson-Rylander AC
Cardiovasc Diabetol; 2019 Feb; 18(1):16. PubMed ID: 30732594
[TBL] [Abstract][Full Text] [Related]
3. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice.
Lin B; Koibuchi N; Hasegawa Y; Sueta D; Toyama K; Uekawa K; Ma M; Nakagawa T; Kusaka H; Kim-Mitsuyama S
Cardiovasc Diabetol; 2014 Oct; 13():148. PubMed ID: 25344694
[TBL] [Abstract][Full Text] [Related]
4. Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat.
Park SH; Farooq MA; Gaertner S; Bruckert C; Qureshi AW; Lee HH; Benrahla D; Pollet B; Stephan D; Ohlmann P; Lessinger JM; Mayoux E; Auger C; Morel O; Schini-Kerth VB
Cardiovasc Diabetol; 2020 Feb; 19(1):19. PubMed ID: 32070346
[TBL] [Abstract][Full Text] [Related]
5. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats.
Lee HC; Shiou YL; Jhuo SJ; Chang CY; Liu PL; Jhuang WJ; Dai ZK; Chen WY; Chen YF; Lee AS
Cardiovasc Diabetol; 2019 Apr; 18(1):45. PubMed ID: 30935417
[TBL] [Abstract][Full Text] [Related]
6. Metabolic cardio- and reno-protective effects of empagliflozin in a prediabetic rat model.
Huttl M; Markova I; Miklankova D; Oliyarnyk O; Trnovska J; Kucera J; Sedlacek R; Haluzik M; Malinska H
J Physiol Pharmacol; 2020 Oct; 71(5):. PubMed ID: 33475091
[TBL] [Abstract][Full Text] [Related]
7. A sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin comparison with insulin shows important effects on Zn
Olgar Y; Turan B
Can J Physiol Pharmacol; 2019 Jun; 97(6):528-535. PubMed ID: 30444646
[TBL] [Abstract][Full Text] [Related]
8. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart.
Li C; Zhang J; Xue M; Li X; Han F; Liu X; Xu L; Lu Y; Cheng Y; Li T; Yu X; Sun B; Chen L
Cardiovasc Diabetol; 2019 Feb; 18(1):15. PubMed ID: 30710997
[TBL] [Abstract][Full Text] [Related]
9. SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice.
Xu L; Nagata N; Nagashimada M; Zhuge F; Ni Y; Chen G; Mayoux E; Kaneko S; Ota T
EBioMedicine; 2017 Jun; 20():137-149. PubMed ID: 28579299
[TBL] [Abstract][Full Text] [Related]
10. Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction.
Connelly KA; Zhang Y; Desjardins JF; Nghiem L; Visram A; Batchu SN; Yerra VG; Kabir G; Thai K; Advani A; Gilbert RE
Cardiovasc Diabetol; 2020 Feb; 19(1):13. PubMed ID: 32035482
[TBL] [Abstract][Full Text] [Related]
11. Dietary salt restriction improves cardiac and adipose tissue pathology independently of obesity in a rat model of metabolic syndrome.
Hattori T; Murase T; Takatsu M; Nagasawa K; Matsuura N; Watanabe S; Murohara T; Nagata K
J Am Heart Assoc; 2014 Dec; 3(6):e001312. PubMed ID: 25468654
[TBL] [Abstract][Full Text] [Related]
12. In a Prediabetic Model, Empagliflozin Improves Hepatic Lipid Metabolism Independently of Obesity and before Onset of Hyperglycemia.
Hüttl M; Markova I; Miklankova D; Zapletalova I; Poruba M; Haluzik M; Vaněčkova I; Malinska H
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768942
[TBL] [Abstract][Full Text] [Related]
13. Empagliflozin improves left ventricular diastolic function of db/db mice.
Moellmann J; Klinkhammer BM; Droste P; Kappel B; Haj-Yehia E; Maxeiner S; Artati A; Adamski J; Boor P; Schütt K; Lopaschuk GD; Verma S; Marx N; Lehrke M
Biochim Biophys Acta Mol Basis Dis; 2020 Aug; 1866(8):165807. PubMed ID: 32353614
[TBL] [Abstract][Full Text] [Related]
14. A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats.
Durak A; Olgar Y; Degirmenci S; Akkus E; Tuncay E; Turan B
Cardiovasc Diabetol; 2018 Nov; 17(1):144. PubMed ID: 30447687
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory Effects of Tofogliflozin on Cardiac Hypertrophy in Dahl Salt-Sensitive and Salt-Resistant Rats Fed a High-Fat Diet.
Kimura T; Nakamura K; Miyoshi T; Yoshida M; Akazawa K; Saito Y; Akagi S; Ohno Y; Kondo M; Miura D; Wada J; Ito H
Int Heart J; 2019 May; 60(3):728-735. PubMed ID: 31105148
[TBL] [Abstract][Full Text] [Related]
16. Complex Positive Effects of SGLT-2 Inhibitor Empagliflozin in the Liver, Kidney and Adipose Tissue of Hereditary Hypertriglyceridemic Rats: Possible Contribution of Attenuation of Cell Senescence and Oxidative Stress.
Trnovska J; Svoboda P; Pelantova H; Kuzma M; Kratochvilova H; Kasperova BJ; Dvorakova I; Rosolova K; Malinska H; Huttl M; Markova I; Oliyarnyk O; Melcova M; Skop V; Mraz M; Stemberkova-Hubackova S; Haluzik M
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638943
[TBL] [Abstract][Full Text] [Related]
17. Amlodipine enhances amelioration of vascular insulin resistance, oxidative stress, and metabolic disorders by candesartan in metabolic syndrome rats.
Sueta D; Nakamura T; Dong YF; Kataoka K; Koibuchi N; Yamamoto E; Toyama K; Yasuda O; Ogawa H; Kim-Mitsuyama S
Am J Hypertens; 2012 Jun; 25(6):704-10. PubMed ID: 22421905
[TBL] [Abstract][Full Text] [Related]
18. Empagliflozin prohibits high-fructose diet-induced cardiac dysfunction in rats via attenuation of mitochondria-driven oxidative stress.
Bugga P; Mohammed SA; Alam MJ; Katare P; Meghwani H; Maulik SK; Arava S; Banerjee SK
Life Sci; 2022 Oct; 307():120862. PubMed ID: 35934058
[TBL] [Abstract][Full Text] [Related]
19. Long-term renal denervation normalizes disrupted blood pressure circadian rhythm and ameliorates cardiovascular injury in a rat model of metabolic syndrome.
Katayama T; Sueta D; Kataoka K; Hasegawa Y; Koibuchi N; Toyama K; Uekawa K; Mingjie M; Nakagawa T; Maeda M; Ogawa H; Kim-Mitsuyama S
J Am Heart Assoc; 2013 Aug; 2(4):e000197. PubMed ID: 23974905
[TBL] [Abstract][Full Text] [Related]
20. A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans.
Michel MC; Mayoux E; Vallon V
Naunyn Schmiedebergs Arch Pharmacol; 2015 Aug; 388(8):801-16. PubMed ID: 26108304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]